Toggle Main Menu Toggle Search

Open Access padlockePrints

MicroRNA-122: A Novel Hepatocyte-Enriched in vitro Marker of Drug-Induced Cellular Toxicity

Lookup NU author(s): Dr Ernest Harpur

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

Emerging hepatic models for the study of drug-induced toxicity include pluripotent stem cell-derived hepatocyte-like cells (HLCs) and complex hepatocyte-non-parenchymal cellular coculture to mimic the complex multicellular interactions that recapitulate the niche environment in the human liver. However, a specific marker of hepatocyte perturbation, required to discriminate hepatocyte damage from non-specific cellular toxicity contributed by non-hepatocyte cell types or immature differentiated cells is currently lacking, as the cytotoxicity assays routinely used in in vitro toxicology research depend on intracellular molecules which are ubiquitously present in all eukaryotic cell types. In this study, we demonstrate that microRNA-122 (miR-122) detection in cell culture media can be used as a hepatocyte-enriched in vitro marker of drug-induced toxicity in homogeneous cultures of hepatic cells, and a cell-specific marker of toxicity of hepatic cells in heterogeneous cultures such as HLCs generated from various differentiation protocols and pluripotent stem cell lines, where conventional cytotoxicity assays using generic cellular markers may not be appropriate. We show that the sensitivity of the miR-122 cytotoxicity assay is similar to conventional assays that measure lactate dehydrogenase activity and intracellular adenosine triphosphate when applied in hepatic models with high levels of intracellular miR-122, and can be multiplexed with other assays. MiR-122 as a biomarker also has the potential to bridge results in in vitro experiments to in vivo animal models and human samples using the same assay, and to link findings from clinical studies in determining the relevance of in vitro models being developed for the study of drug-induced liver injury.


Publication metadata

Author(s): Kia R, Kelly L, Sison-Young RLC, Zhang F, Pridgeon CS, Heslop JA, Metcalfe P, Kitteringham NR, Baxter M, Harrison S, Hanley NA, Burke ZD, Storm MP, Welham MJ, Tosh D, Kuppers-Munther B, Edsbagge J, Lewis PJS, Bonner F, Harpur E, Sidaway J, Bowes J, Fenwick SW, Malik H, Goldring CEP, Park BK

Publication type: Article

Publication status: Published

Journal: Toxicological Sciences

Year: 2015

Volume: 144

Issue: 1

Pages: 173-185

Print publication date: 01/03/2015

Online publication date: 18/12/2014

Acceptance date: 01/01/1900

Date deposited: 01/07/2016

ISSN (print): 1096-6080

ISSN (electronic): 1096-0929

Publisher: Oxford University Press

URL: http://dx.doi.org/10.1093/toxsci/kfu269

DOI: 10.1093/toxsci/kfu269


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
AstraZeneca
Biotechnology and Biological Sciences Research Council of UK
ICON
Medical Evaluation Unit
Stem Cells for Safer Medicines (SC4SM)
Wellcome Trust
GlaxoSmithKline
115336Innovative Medicines Initiative MIP-DILI programme
G1000417/94909North West England MRC - Medical Research Council
G0700654Medical Research Council (MRC) Centre for Drug Safety Science

Share